Serenac

# Serenac ## Overview - **Classification**: Atypical Antipsychotic - **Mechanism**: Primarily blocks D2 dopamine and 5-HT2A serotonin receptors. Also has affinity for alpha1-adrenergic and H1 histamine receptors. ## Primary Indications 1. **Schizophrenia** - Management of acute and chronic schizophrenia. 2. **Bipolar I Disorder** - Monotherapy or adjunct for acute manic/mixed episodes. 3. **Major Depressive Disorder (MDD)** - Adjunctive treatment for MDD. ## Adult Dosing ### Standard Dosing **Schizophrenia** - **Dose**: Initial **2 mg PO once daily**. Titrate slowly. - **Frequency**: Once daily - **Route**: Oral - **Target Dose**: **4-8 mg PO once daily** - **Maximum Dose**: **12 mg PO once daily** **Bipolar I Disorder (Monotherapy)** - **Dose**: Initial **4 mg PO once daily**. - **Frequency**: Once daily - **Route**: Oral - **Target Dose**: **4-10 mg PO once daily** - **Maximum Dose**: **12 mg PO once daily** **Major Depressive Disorder (Adjunctive)** - **Dose**: Initial **1 mg PO once daily**. - **Frequency**: Once daily - **Route**: Oral - **Target Dose**: **1-4 mg PO once daily** - **Maximum Dose**: **6 mg PO once daily** ### Dose Adjustments - **Renal Impairment**: CrCl < 50 mL/min: Start at **half initial dose**, titrate slowly. Max dose reduced by 50%. - **Hepatic Impairment**: Moderate to severe: Start at **half initial dose**, titrate slowly. Max dose reduced by 50%. - **Elderly Patients**: Start at **half initial dose (e.g., 1-2 mg/day)**. Titrate very slowly. Monitor closely for orthostasis and sedation. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Generally **not recommended**. - **Special Notes**: Safety and efficacy have not been established. ### Infants (1-12 months) - **Dose**: Generally **not recommended**. - **Special Notes**: Safety and efficacy have not been established. ### Children (6-12 years) **Irritability associated with Autistic Disorder** - **Dose**: Initial **0.5 mg PO once daily**. - **Frequency**: Once daily - **Titration**: Increase by **0.5 mg every 7 days** as tolerated. - **Target Dose**: **0.02-0.06 mg/kg/day**. - **Maximum**: **6 mg PO once daily**. - **Special Notes**: Closely monitor for weight gain and metabolic changes. ### Adolescents (13-18 years) - **Dose**: Approach adult dosing, but start with lower initial doses (e.g., **2 mg PO once daily**). - **Frequency**: Once daily - **Maximum**: Adult maximum dose of **12 mg PO once daily**. - **Special Notes**: Titrate slowly based on response and tolerability. ## Safety Information ### Contraindications - **Absolute**: Known hypersensitivity to Serenac or its components. - **Absolute**: Co-administration with other drugs known to prolong the QT interval. - **Relative**: Severe CNS depression or comatose states. ### Common Adverse Effects - **Very Common (>10%)**: Somnolence, Weight gain, Dizziness, Headache. - **Common (1-10%)**: Akathisia, Nausea, Constipation, Dry mouth, Dyslipidemia, Hyperglycemia, Orthostatic hypotension. - **Serious but Rare**: Neuroleptic Malignant Syndrome (NMS), QT prolongation/Torsades de Pointes, Seizures, Agranulocytosis, Tardive Dyskinesia (TD), Increased mortality in elderly patients with dementia-related psychosis. ### Key Drug Interactions - **CYP3A4 Inducers (e.g., Carbamazepine, Rifampin)**: May significantly decrease Serenac plasma levels. Consider increasing Serenac dose. - **CYP3A4/2D6 Inhibitors (e.g., Ketoconazole, Paroxetine)**: May significantly increase Serenac plasma levels. Consider decreasing Serenac dose. - **CNS Depressants (e.g., Alcohol, Benzodiazepines)**: Increased risk of sedation and respiratory depression. Avoid concurrent use. - **QT-prolonging Drugs (e.g., Amiodarone, Quinidine)**: Increased risk of life-threatening arrhythmias. **Contraindicated**. ## Monitoring & Follow-up - **Before Treatment**: Weight, Body Mass Index (BMI), fasting glucose, lipid profile, blood pressure, ECG. - **During Treatment**: - **Weight/BMI**: Monthly for 3 months, then quarterly. - **Fasting Glucose/Lipids**: 3 months after initiation, then annually. - **Blood Pressure**: Regularly (e.g., at each visit). - **ECG**: Baseline and as clinically indicated (if QT concern arises). - **AIMS Scale**: Annually for signs of Tardive Dyskinesia. - **Clinical Signs**: Monitor for extrapyramidal symptoms (EPS), excessive sedation, signs of metabolic changes (e.g., polyuria, polydipsia), and signs of NMS (e.g., fever, rigidity, altered mental status). ## Clinical Pearls - 💡 **Tip 1**: Administer Serenac consistently, with or without food. - 💡 **Tip 2**: Titrate dose slowly to minimize orthostatic hypotension and sedation, especially during initiation. - 💡 **Tip 3**: Educate patients on potential for weight gain and metabolic changes; encourage regular exercise and healthy diet. - 💡 **Tip 4**: Advise patients to immediately report any unusual muscle movements or high fever. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.